ALLOY THERAPEUTICS
Updates & Highlights
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation A...
Business Wire · 17 days ago
Staying private: Alloy Therapeutics’ $40m Series E fuels company expansion
Staying private: Alloy Therapeutics’ $40m Series E fuels company expansion
BioXconomy · 30 days ago
Alloy Therapeutics: $40 Million Series E At $1 Billion Valuation Raised To Scale AI-Driven Biotech Infrastructure
Alloy Therapeutics: $40 Million Series E At $1 Billion Valuation Raised To Scale AI-Driven Biotech Infrastructure
Pulse 2.0 · about 1 month ago
Recent Openings
View all 1 jobsCulture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Alloy Therapeutics?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentAlloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Business Wire · 17 days ago
Staying private: Alloy Therapeutics’ $40m Series E fuels company expansion
Staying private: Alloy Therapeutics’ $40m Series E fuels company expansion
BioXconomy · 30 days ago
Alloy Therapeutics: $40 Million Series E At $1 Billion Valuation Raised To Scale AI-Driven Biotech Infrastructure
Alloy Therapeutics: $40 Million Series E At $1 Billion Valuation Raised To Scale AI-Driven Biotech Infrastructure
Pulse 2.0 · about 1 month ago
Alloy Therapeutics Raises $40M in Series E Funding
Alloy Therapeutics Raises $40M in Series E Funding
FinSMEs · about 1 month ago
Alloy Therapeutics Secures $40M To Accelerate AI Drug Development
Alloy Therapeutics Secures $40M To Accelerate AI Drug Development
Ventureburn · about 1 month ago
Alloy Therapeutics Raises $40M Series E at $1B Valuation to Expand AI-Driven Drug Development Platform
Alloy Therapeutics Raises $40M Series E at $1B Valuation to Expand AI-Driven Drug Development Platform
citybiz · about 1 month ago
Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure
Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure
Business Wire · about 1 month ago
Boost for Cambridge as US company Alloy Therapeutics shows real Vigilance
Boost for Cambridge as US company Alloy Therapeutics shows real Vigilance
Business Weekly · about 1 month ago
Biogen to use Alloy Therapeutics’ Anticlastic ASO platform
Biogen to use Alloy Therapeutics’ Anticlastic ASO platform
BioWorld News · about 1 month ago
Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform
Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform
TradingView · about 1 month ago
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
Business Wire · about 1 month ago
Alloy Therapeutics Appoints Alexander Titus to Lead New AI-Driven Vigilance Division
Alloy Therapeutics Appoints Alexander Titus to Lead New AI-Driven Vigilance Division
citybiz · about 2 months ago
Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response
Alloy Therapeutics Appoints Alexander Titus, Ph.D., to Lead New Vigilance Division Focused on Biosecurity and Rapid Therapeutic Response
Business Wire · about 2 months ago
AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform
AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform
Yahoo Finance · 2 months ago
AbbVie (ABBV) Partners with Alloy Therapeutics for Advanced Anti
AbbVie (ABBV) Partners with Alloy Therapeutics for Advanced Anti
GuruFocus · 2 months ago
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
Business Wire · 2 months ago
Alloy Therapeutics and Abbvie partner on antibody platform
Alloy Therapeutics and Abbvie partner on antibody platform
BioWorld News · 2 months ago
Swiss Rockets and Alloy Therapeutics form RLT partnership
Swiss Rockets and Alloy Therapeutics form RLT partnership
BioWorld News · 4 months ago
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
Business Wire · 4 months ago
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
Yahoo Finance · 4 months ago